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Atherosclerosis is a chronic inflammatory disorder characterised by the accumulation of monocytes/macrophages, smooth muscle
cells, and lymphocytes within the arterial wall in response to the release of proinflammatory molecules. Such accumulation results
in the formation of the atherosclerotic plaque, which would eventually evolve to complications such as total artery occlusion,
rupture, calcification, or aneurysm. Although the molecular mechanism responsible for the development of atherosclerosis is
not completely understood, it is clear that the immune system plays a key role in the development of the atherosclerotic plaque
and in its complications. There are multiple antigenic stimuli that have been associated with the pathogenesis of atherosclerosis.
Most of these stimuli come from modified self-molecules such as oxidised low-density lipoproteins (oxLDLs), beta2glycoprotein1
(β2GP1), lipoprotein a (LP(a)), heat shock proteins (HSPs), and protein components of the extracellular matrix such as collagen
and fibrinogen in the form of advanced glycation-end (AGE) products. In addition, several foreign antigens including bacteria
such as Porphyromonas gingivalis and Chlamydia pneumoniae and viruses such as enterovirus and cytomegalovirus have been
associated with atherosclerosis as potentially causative or bystander participants, adding another level of complexity to the analysis
of the pathophysiology of atherosclerosis. The present review summarises the most important scientific findings published within
the last two decades on the importance of antigens, antigen stimulation, and adaptive immune responses in the development of
atherosclerotic plaques.
Copyright © 2008 Natalia Milioti et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. ATHEROSCLEROTIC PLAQUE FORMATION
It is diﬃcult to identify the factors responsible for the
initiation of the atheroma lesion and/or the order in which
these factors contribute to plaque formation. Nevertheless,
it is known that endothelial dysfunction and high levels
of circulating cholesterol, as oxLDL, play a key role in the
proinflammatory process that triggers the first steps in the
development of atherosclerotic plaques [1, 2]. Whatever
the cause, these steps are characterised by an initially
reversible accumulation of lipid-laden macrophages in the
subendothelial space as a consequence of the increasing
migration of blood-derived monocytes. These cells accu-
mulate at focal points within the vascular wall of medium
and small size arteries driven by chemokines and adhesion
molecules produced by the damaged endothelium [3–5].
Monocytes diﬀerentiate in situ into macrophages which
express membrane receptors such as Toll-like receptors
and scavenger receptors that participate in the clearance
of oxLDL [6, 7]. Lymphocytes can also transmigrate and
accumulate within the arterial wall from the very earliest
stages (Figure 1) [8].
As the inflammatory process becomes chronic, smooth
muscle cells also start to migrate from the media into
the intima layer of the vessel, in response to chemokines
and aided by the release of membrane metalloproteinases
(MMPs) that enable them to break through the elastic lamina
into the subendothelial space (Figure 1) [9, 10]. Persistence
of inflammation creates a vicious circle of cell migration,
dediﬀerentiation of smooth muscle cells, production of
chemotactic and proinflammatory mediators, and cell death
leading to vascular wall remodelling and formation of a new
layer called neointima (Figures 1 and 2) [11, 12].
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Figure 1: Inflammatory basis of atherosclerotic plaque formation. Led by inflammatory signals derived from the damaged endothelium,
monocytes and lymphocytes migrate into the vessel wall. Monocytes diﬀerentiate into macrophages that recognise and phagocytiose oxidised
LDL particles. The protein component of the LDL particle is processed and presented in the form of peptides by macrophages (also by
dendritic cells) to T-lymphocytes in the context of the major histocompatibility complex class II (MHC-II). Other self or foreign antigens
that may gain access to the vascular wall can also trigger similar mechanisms. It is believed that most of these lymphocytes diﬀerentiate
in situ, under the influence of the specific antigen stimulation, into eﬀector T-cells, but this has yet to be demonstrated. Upon activation,
both macrophages and lymphocytes release a range of proinflammatory molecules including chemokines which stimulate the migration of
smooth muscle cells (SMCs) from the media. SMCs contribute to foam cell and fibrous cap formation. This process is facilitated by cytokines
such as IFNγ and TNFα secreted by proatherogenic Th1 cells and also IL-12 secreted by macrophages and foam cells. Eventually foam cells
die by apoptosis in situ leaving nondegradable cholesterol crystals that form the lipid core of the plaque.
Neointima formation is a complex phenomenon that
occurs in response to vessel wall damage in which repair and
injury mechanisms give birth to areas rich in proinflamma-
tory cells and collagen deposition [11, 12]. It is within these
areas where a close contact between macrophages, dendritic
cells (DCs), and lymphocytes has been reported. It has been
speculated that the interaction between lymphocytes and
DCs within the neointima is responsible for the development
of local immune responses against exogenous and endoge-
nous atherogenic antigens. These immune responses may
contribute to cell death by apoptosis and accumulation of
nondegradable cholesterol, contributing to the formation of
the lipid core of the atherosclerotic plaque [15–18]. However,
the precise mechanisms involved are not yet clear.
2. THE IMMUNOLOGIC NATURE OF
THE ATHEROGENIC PROCESS
Atherosclerosis belongs to the group of chronic inflam-
matory diseases in which the cellular components of
the immune system play a key role in its development
and complications. The chronic accumulation of mono-
cytes/macrophages, smooth muscle cells, and T-lymphocytes
in response to the accumulation and release of proin-
flammatory molecules within the arterial wall constitutes
the hallmark of a developing atherosclerotic plaque [15].
Although most of the antigenic stimuli that occur within
atherosclerotic plaques come from modified self-molecules,
the immune response triggered is remarkably similar to
inflammatory reactions mounted against microbial organ-
isms [19, 20]. The list of atherosclerosis-related antigens
range from oxidised low-density lipoproteins (oxLDL), heat
shock proteins (HSP) to protein components of the extra-
cellular matrix such as collagen and fibrinogen (Table 1).
On the other hand, the disputed role of foreign antigens,
such as viruses and bacteria, in atherogenesis as causative
or bystander participants in its development introduces
another level of complexity to the analysis. This review
summarises the most important scientific findings published
within the last 2 decades on the importance of antigens,
antigen stimulation, and adaptive immune responses in the
development of atherosclerotic plaques.
3. ATHEROSCLEROSIS-RELATED ANTIGENS
As stated above, both endogenous and exogenous antigens
are involved in atherogenesis. Table 1 summarises some
of the most studied antigens in relation to atherosclerotic
plaque formation.
3.1. Oxidised low-density lipoprotein (oxLDL)
OxLDL remains one of the most studied antigens in athero-
genesis (Figure 3). LDL does not normally trigger immune
responses in its native state; however when it gets oxidised, it
can initiate inflammation-leading to atherosclerosis. OxLDL
is considered a neoantigen, a term used to describe modified
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Table 1: Antigens that have been reported to be involved in atherogenesis.
Antigen Reference
Autoantigens Oxidised low-density lipoprotein (LDL) [21–23]
Beta2glycoprotein1 (beta2GP1) [24–26]
Lipoprotein a (LP(a)) [27]
Lipoprotein-lipase (LPL) [28]
Advanced glycation-end products (AGE) [29]
Heat-shock proteins [30, 31]
Collagen [32–34]
Fibrinogen [35]
Microbial antigens Porphyromonas gingivalis [36, 37]
Chlamydia pneumoniae [38–49]
Bacteroides forsynthus [36]
Streptococcus mutans [36, 37, 50]
Helicobacter pylori [51–64]
Echerichia coli [65, 66]
Enterovirus [67–69]
Cytomegalovirus [22, 70–78]
Viperin [79]
self-antigens for which normally the immune system is
tolerant but which upon modification have the poten-
tial to excerpt autoreactive immune responses. Modified
lipoprotein particles have the capacity to interact with the
endothelium, triggering their accumulation and retention
in the subendothelial space. The retained oxLDL particles
induce macrophage foam cell formation, smooth muscle cell
migration and proliferation [80] and, in addition, stimulate
the secretion of inflammatory cytokines. OxLDL also induces
the expression of adhesion molecules promoting endothelial
cell dysfunction and leukocyte extravasation [81].
In atherosclerosis, increased levels of oxLDL have been
found in the serum of patients admitted with acute myocar-
dial infarction, and immunohistochemical studies revealed
the presence of oxLDL within atherosclerotic plaques [82–
85]. Proteoglycans, contained within the extracellular matrix
of the arterial wall, interact with oxLDL via their carbo-
hydrate groups, glycosamynoglycans (GAGs) as it has been
described in vitro and in immunohistochemical studies
using defective LDL unable to bind to GAGs [86]. The
initial interaction of LDL with the proteoglycans leads
to structural changes that expose the GAG-binding sites
contributing to LDL retention. This interaction is mediated
by apolipoprotein B (ApoB), which is the main protein
component of LDL particles [87]. At least two proteoglycan-
binding sequences within ApoB have been identified and
shown to be necessary for retaining LDL particles within
the intimal layer [80]. The interaction between the ApoB
and the GAGs also facilitates LDL oxidation by oxygen-
reactive species released by vascular cells or as a result
of enzymatic modifications driven by endothelial cells,
smooth muscle cells, or macrophages present within the
atherosclerotic plaques [88]. Cholesterol molecules also
have a high aﬃnity for GAGs and for the LDL receptor.
The accumulation of oxLDL within atherosclerotic plaques
has been demonstrated, among other methods, by using
monoclonal antibodies such as DLH3 that binds specifically
to oxLDL but non to native LDL (nLDL) [89]. DLH3 binds
to the oxidised phosphatidylcholine groups (oxPC) and to
the phosphatidylcholine (PC)-apoB adducts formed when
LDL is oxidised. PC-apoB adducts are considered to be
the principal antibody targeted epitopes on the surface of
the particles. Furthermore, oxPC also promote endothelial-
monocyte adhesion by inducing the secretion of monocyte
chemoattractant protein 1 (MCP-1) by endothelial cells
[23], and can also be recognised by scavenger receptors
such as CD36 which are involved in the oxLDL uptake by
macrophages [90–93].
The initial interaction of proteoglycans with the LDL
within the arterial wall leads lipid modifications that expose
GAG binding sites. Cholesterol, cholesteryl esters and phos-
pholipids are the main targets for lipid modifications and
their role in the development of the disease has been
extensively evaluated. These modifications play an important
role, as stated above, in LDL retention within the arterial
wall which is also facilitated by interactions with surface
molecules such as apoE and lipoprotein lipase expressed on
macrophages [94].
However, most studies have focused on the role of the
oxidised phospholipids (oxPLs) [95]. Peroxidation of the
phospholipids starts in the fatty acids. The decomposition
of the fatty acids generates a spectrum of reactive species
such as malondialdehyde (MDA), 4-hydroxynonenal, and
1-palmitoyl-2-(5-oxovaleroyl)-glycero-3-phosphocholine
molecule (POVPC) that can oxidise apolipoprotein B
(ApoB) as well as other lipids, resulting in ox-PLs and
oxidised protein-lipid adducts [96, 97].
It has also been established that oxLDL acts as a
chemoattractant for monocytes allowing them to infiltrate
the lesion site. OxLDL has been shown to induce monocyte
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Figure 2: Morphological features of advanced atherosclerotic
plaques. (a) and (b) show sections from a human carotid artery; (c)
and (d) are sections from an apoE deficient mouse brachiocephalic
artery. Sections (a) and (c) have been stained with haematoxylin
and eosin and sections (b) and (d) with van Gieson staining (used
to demonstrate the increase of collagen deposition and development
of elastic fibres, a characteristic feature of the atherogenic process.
A positive staining is depicted by a brown colour). L: lumen of the
vessel; SR: shoulder region (it is believed to contain large numbers
of proinflammatory cells including macrophages and lymphocytes,
and it is the site related with the onset of the development
of the atherosclerotic plaque); FC: fibrous cap (It also contains
large numbers of mononuclear infiltrate and smooth muscle cells
that have migrated from the media layer (M) and proliferated in
response to the local inflammatory stimuli. It is also characterised
by high collagen deposition and little or no endothelial cells); LC:
lipid core (it contains mainly macrophage and smooth muscle
cell-derived foam cells, apoptotic cells, and cholesterol crystals.
Older lesions may also display signs of calcification). Contrasting
diﬀerences can be recognised in the anatomic development of
atherosclerotic plaques between human and mouse including the
hypertrophy associated with the proliferation of the smooth muscle
cells in the media layer and the fibrous cap. In humans, some lesions
may also contain signs of intraplaque haemorrhage. Signs of plaque
rupture are usually best recognised in mouse (reviewed in [13, 14]).
adhesion to the endothelium by upregulating the expres-
sion of adhesion molecules on their surface, by inducing
macrophage major histocompatibility class II (MHC-II) &
LeuM3 cell surface expression and by accelerating monocyte
diﬀerentiation in to macrophages [22]. Endothelial cells are
also capable of oxidising LDL, contributing to a continuous
generation of oxLDL within the lesion site, and to attract
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Figure 3: Schematic representation of the low-density lipoprotein
particle (LDL). The LDL particle has a size of approximately 21–
24 nm and is the main transporter of unesterified cholesterol,
cholesterol esters, and triglycerides in the blood. It contains an
outer layer composed of phospholipids and unesterified cholesterol
in which a single protein is embedded, the apolipoprotein B-100
(apoB-100). These components are more susceptible to oxidation
by free radicals in the subendothelial space during inflammation.
They are also targets for the recognition of the LDL by scavenger
receptors, proteoglycans, and low-density lipoprotein receptor
(LDLr). The core of the particle contains primarily cholesterol
esters and triglycerides. In atherogenesis, a large number of IgM
antibodies are created in response to oxidative stress-modified
phospholipids, whereas IgG antibodies and T-cell clones are
generated against apoB-100.
more monocytes. Other inflammatory mediators such as
interleukin 1β (IL-1β), tumor necrosis factor alpha (TNF-
α) and monocyte colony stimulating factor (M-CSF) can
induce the expression of the oxLDL receptor (oxLDL-R) on
the surface of endothelial cells, thus further contributing to
oxLDL accumulation [22, 98].
Scavenger receptors expressed by macrophages play a piv-
otal role in LDL accumulation; such receptors include CD36
(a membrane glycoprotein), CD68, CXCL16, the scavenger
receptors A & B1 (SR-A & SR-B1), and the lectin-type oxi-
dised low-density lipoprotein receptor 1 (LOX1) [98, 99]. It
is believed that the high expression of the scavenger receptors
on macrophages mediates lipid accumulation and foam cell
formation [100]. Following proteolytic processing inside the
cell, fragments of the oxidised-modified ApoB protein are
displayed on the surface of macrophages bound on MHC-
II molecules. This process also leads to the upregulation of
important molecules such as toll-like receptors TLR2 and
TLR4 that induce proatherogenic immune responses [36].
There is also evidence that products of the inflammatory
process such as endogenous HSP60 and LDL oxidation
derivatives bind TLR4-CD14 complexes on monocytes and
macrophages eliciting proinflammatory responses [30, 101,
102]. This has been associated with an enhanced production
of cytokines, an enhancement of oxLDL uptake, and an
increase adhesion of these cells to the endothelium mediated
by IL-8 and NFκB synthesis [101, 103].
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The large size of the LDL molecule (2 × 106 kDa)
favours the exposure of many epitopes recognised by the
antibodies generated, mainly IgM. OxLDL is known to be
a very potent immunogen and the antibodies generated in
response to its modifications are able to bind to many other
similarly modified endogenous proteins [104]. It has been
demonstrated that there is a molecular mimicry between the
head of the PC groups of oxLDL and the PC groups expressed
on the surface of many pathogens such as Streptococcus
pneumoniae [105], which indicates that during an infection,
more autoantibodies against oxLDL might be generated.
Studies using experimental animal models have shown that
epitopes generated during LDL oxidation, such as oxPC, are
also generated on the surface of bacteria and on the surface
of endothelial cells [21]. These epitopes bind to antibodies
that will mediate removal of oxLDL and apoptotic cells [106].
Some of the oxidation-specific epitopes present on oxLDL
are also presented on the surface of apoptotic cells in the
lesion site, and play a role in the clearance of the damaged
oxidised lipid molecules and of apoptotic cells generated
during the inflammatory response within plaques [21].
3.2. Immunisation using oxLDL confers
atheroprotection
A series of studies have shown the beneficial side of oxLDL.
These studies have demonstrated that immune responses
against this lipoprotein may protect against the development
of the disease [107–111]. The first report came from Palinski
et al. which immunised LDL receptor-deficient rabbits using
homologous MDA-LDL. This treatment induced high titres
of antibodies displaying equal specificity as those risen by
the native particle and significantly reduced atherosclerotic
plaque development [107]. Studies from other laboratories
confirmed these results and showed that immunisation of
hypercholesterolemic rabbits reduced T cell and oxLDL
immunoreactivity within the neointima of immunized ani-
mals [108].
The eﬀect of LDL immunisation on atheroprotection has
also been assessed using mouse models of the disease. George
et al. was the first to report the eﬀect of MDA modified LDL
immunisation in apoE-deficient mice (apoE−/−). Immunised
mice developed high titres of anti-MDA-LDL antibodies and
the treatment significantly reduced lesion size at the aortic
sinus by more than half when compared with their control
littermates immunised with PBS. However, they did not
find diﬀerences between the groups with respect to cellular
composition of the atherosclerotic plaques [109]. Later on,
Freigang et al. showed that LDL receptor-deficient mice
(LDLR−/−) immunised with homologous malondialdehyde-
modified LDL (MDA-LDL) induced the synthesis of anti-
bodies of diﬀerent classes against distinctive epitopes on
oxLDL and that this antibody response is significantly
correlated with a reduction by approximately 40% of lesion
size. However, they also showed that immunisation with
MDA-LDL raised equivalent amounts of both T helper 1
(Th1)-related IgG2a and Th2-dependent IgG1 antibodies
[110]. On the other hand, an elegant study carried out
by Zhou et al. provided evidence of the involvement and
control of the production of oxLDL-induced antibodies by
T cells. They immunised apoE−/− mice with homologous
plaque homogenates or homologous MDA-LDL. They found
that both antigen preparations reduced lesion development.
The protective eﬀect was associated with a specific raise
of T-cell-dependent IgG antibodies against MDA-LDL and
oxidised phospholipids which are correlated with the reduc-
tion in plaque size and circulating cholesterol levels [111].
Despite these demonstrations, the protective role of oxLDL
during physiological conditions remains unknown and the
immunological mechanisms related with it have not yet been
fully studied.
3.3. β2-glycoprotein I (β2GpI)
Rheumatic patients suﬀering from the antiphospholipid
syndrome produce large amounts of antiphospholipid anti-
bodies. The standard phospholipid used to detect antiphos-
pholipid antibodies is cardiolipin, which is prone to per-
oxidation and is also an important component of the
oxLDL molecule [21]. A cofactor involved in anticardiolipin
binding is the β2-glycoprotein I (β2GpI), a positively charged
plasma protein circulating in the blood and also present in
platelets and endothelial cells in atherosclerotic plaques [25].
Binding to the aPL antibodies requires a structural change
in β2GpI which occurs when the protein binds to negatively
charged phospholipids present in the atherosclerotic plaques.
When transgenic animals are immunised with β2GpI, the
atherosclerosis process is accelerated [26]. It has been
reported that β2GpI can function as a scavenger receptor
to mediate lipid engulfment by macrophages. Furthermore,
histological studies showed that β2GpI is located in the
subendothelial space in areas rich in CD4+ T cells [24]. A
recent study showed that the adoptive transfer of β2GpI
reactive T cells can promote the generation of fatty streaks
in LDL−/− mice, indicating that cellular autoimmunity is
involved in the pathogenesis of atherosclerosis [25].
3.4. Lipoprotein(a) [Lp(a)]
Lp(a) is an antigen of relevance to atherosclerosis devel-
opment [27]. Lp(a) is associated with apolipoprotein(a)
(Apo-A), another glycoprotein. Lp(a) is present in the
atherosclerotic plaques bound to fibrin. Furthermore, it
may be internalised by macrophages within the plaques and
induce the expression and secretion of chemoattractants
from endothelial cells, thus triggering the attraction of
monocytes in to atherosclerotic plaques. This eﬀect is
specifically attributed to the Apo-A component and suggests
that in the presence of high levels of Apo-A, monocyte
recruitment in to the vascular wall is favoured. The precise
nature of the chemoattractant involved is not known yet, but
GM-CSF and MCP-1 have already been discarded [27].
3.5. Lipoprotein-lipase (LPL)
A further self-antigen involved in lupus-related atheroscle-
rosis is LPL [28]. It is a member of the lipase family that
hydrolyses triglyceride molecules on lipoprotein molecules.
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LPL activity is significantly decreased with the progression
of the disease due to the generation of anti-LPL antibodies
[112, 113]. The hypothesis that has been formulated is that
these antibodies might bind to LPL molecules on the surface
of endothelial cells and obstruct lipid degradation by LPL,
thus promoting lipid accumulation in the atherosclerotic
plaques [113].
3.6. Advanced glycation end (AGE) products
A recent study suggests a possible role of AGE as facilitators
of antigenic stimulation in atherosclerosis by promoting the
maturation of dendritic cells (DCs) [29]. AGE products
stimulate the upregulation of costimulatory and antigen
presenting molecules on DCs which in turn causes T
cell proliferation through the secretion of proinflammatory
cytokines. This activation is mediated, at least in part by
the upregulation of the receptors for AGE (RAGE) and
the scavenger receptor A (SR-A), which is responsible for
regulating cholesterol accumulation on DCs through the
Jnk signaling pathway [29]. Immunohistological studies have
confirmed the expression of AGE, as well as AGE receptors
within atherosclerotic lesions. Cells expressing high levels of
RAGE have been found located close to AGE, where normal
RAGE is expressed in low levels in the endothelium [114,
115]. SR-A knock-out mice have decreased atherosclerotic
lesions, therefore suggesting an indirect link between AGE
stimulation and the development of atherosclerosis in these
animals [116].
3.7. Heat shock proteins (HSPs)
HSPs are released from stressed endothelial cells and can act
as chaperones in the process of denaturation of other pro-
teins. They can induce the production of specific antibodies
which usually accelerate atherosclerotic plaque development
when used to immunise experimental animals [26]. Human
and microbial HSP60 activate vascular endothelial cells
and macrophages directly through CD14 and p38 mitogen-
activated protein kinase signalling pathway in a similar man-
ner as bacterial lipopolysaccharide (LPS) [30], leading to IL-6
and TNF-α secretion and promotion of atherosclerosis. HSPs
are highly conserved among diﬀerent species. Antibodies
involved in the atherosclerotic development recognise both
human and microbial HSPs [31].
3.8. Bacteria-derived antigens
The potential relationship between bacterial infections and
the induction of atherosclerosis has been studied in diﬀerent
groups of cardiovascular patients including those who
develop the disease but that lack the conventional risk factors
associated with it such as hypercholesterolemia, high blood
pressure, smoking and diabetes [51]. It has been speculated
that bacterial infection may have a direct cytopathic eﬀect
on the vascular wall or that could act indirectly through the
induction of an autoimmune inflammatory response involv-
ing mechanisms such as molecular mimicry and epitope
spreading to generate atherosclerosis [19]. Several microbial
components known to ligate pattern recognition receptors or
heat shock proteins and unmethylated CpG DNA have been
reported as ligands for toll-like receptors (TLRs), and there-
fore, have the potential to induce atherosclerosis [117]. TLRs
are part of the sensing mechanisms in response to infections
but it has been suggested that they may also play a contradic-
tory role in inflammation leading to atherosclerosis. There
is evidence showing that endothelial cells and macrophages
in atherosclerotic lesions can upregulate TLR expression
in response to microbial antigens [36]. It is known that
autoantibodies such as those binding to endogenous human
HSP60 and oxidised LDL can also activate TLR4 and induce
proatherogenic immune responses. The response involves
the secretion of proinflammatory cytokines, MMPs, and
other inflammatory mediators (nitric oxide, endothelin-1)
[118, 119].
An example is Porphyromonas gingivalis which has been
detected within atherosclerotic plaques [37]. The inflamma-
tory action of P. gingivalis fimbriae was shown to be mediated
by ligation of TLR2, TLR4, CD14, and beta2-integrins and
also by the upregulation of nuclear factor kappa-B (NF-
κB). It has also been observed that P. gingivalis fimbriae
may promote atherosclerotic plaque rupture by inducing the
secretion of MMPs [120–122]. Other pathogens studied in
relation to atherosclerosis are Bacteroides forsynthus, where
the protein A secreted by the bacterium acts through CD14
and TLR2 ligations to induce atherosclerosis, whereas in the
case of Streptococcus mutans it is the protein AgI/II that acts
through CD14 and TLR4 [37].
Similar mechanisms have been described for Chlamy-
dophila pneumoniae (C. pneumoniae) infection where LPS
and bacterial HSP act as ligands to TLRs. C. pneumoniae is
an intracellular prokaryotic pathogen that infects humans
provoking distinct forms of pneumonia, and it has been
also proposed that it may cause chronic inflammatory
diseases such as atherosclerosis [38]. Chlamydial LPS has
been shown to induce macrophage foam cell formation
and chlamydial HSP60 is known to contribute to LDL
oxidation in the presence of macrophages on the lesion site.
The presence of C. pneumoniae within atheroma lesions
has been detected by PCR and immunohistochemistry.
However, detection is sometimes diﬃcult due to phases
of activity and latency of the pathogen [123, 124]. The
pathogen has been located within DCs in close proximity
to T cells [125] but the precise mechanisms responsible
for the induction of immune activation and atherosclerosis
development remain to be clarified. There is evidence that
patients with acute myocardial infarction have higher titres
of antibodies against C. pneumoniae than control patients
[126]. Moreover, C. pneumoniae has been also extracted
and cultured from atherosclerotic plaques [125, 127, 128].
Experiments carried out in animal models demonstrated the
induction of atherosclerosis by inoculation of C. pneumoniae
[129]. C. pneumoniae can persistently infect epithelial cells
and macrophages within human atherosclerotic plaques
causing a chronic and nonlytic infection [128]. Immune
responses against Chamydia spp. infection mainly involve
CD4+ T-helper (Th)1 cells and antibodies, although other
components such as CD8+ T cells also play a key role
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[130–132]. The relative contribution of these components
to protection depends on several factors, such as the site of
infection, whether it is a primary or secondary infection,
and whether the infection is acute or persistent [133].
However, despite all the evidence supporting the role of
Chlamydia infection in the development of atherosclero-
sis, its correlation with the development of complications
remains controversial. A key element to the debate is the
failure of recent human clinical trials and animal studies
aiming to investigate the secondary preventive eﬀect of
antibiotics on atherosclerosis [128, 129, 134]. In these
studies, antibiotic therapy was eﬀective in clearing the acute
infection, but failed to influence the atherogenic properties
of C. pneumoniae unless the therapy was started early during
the acute infection [134]. It has been hypothesised that
this may be due to a sequestration of the organism within
atherosclerotic plaques, that makes it inaccessible to both
antibiotics and the cellular components of the immune
response.
The microorganism Helicobacter pylori—a cause of gas-
trointestinal infections—has been also found to be present
in atherosclerotic lesions but completely absent from healthy
arteries [52, 53]. However, immunohistochemical studies
could not detect its presence in the lesions but instead
there was a strong cross-reactivity of the antibodies to the
diﬀerent elements of the plaque related to the acceleration of
inflammatory events and plaque destabilisation.
Cross-reactivity has also been observed with antibodies
against human HSP60 and E. coli-derived GroEL, an HSP
[65]. The generation of anti-HSP antibodies can induce
autoimmune reactions binding to HSP on endothelial cells
at the lesion site where it is expressed at high levels due
to shear stress triggered by blood pressure, stimulation by
oxLDL in situ or by inducing the secretion of proinflam-
matory cytokines. The down stream eﬀects are endothelial
and macrophage damage and subsequent inflammatory
events that lead to the pathogenesis of atherosclerosis
[135–137].
3.9. Virus-derived antigens
Viruses have also been postulated as promoters of atheroscle-
rosis. One of the most closely linked to this disease is
cytomegalovirus. This virus infects the majority of the
human population by targeting SMCs and endothelial cells
producing a latent type of infection [138–142]. US28, one
of the viral proteins expressed on the cell surface of the
cytomegalovirus after infection, is a chemoattractant for
SMCs. US28 and UL122 proteins were found to have an
11aa sequence homologous to human HSP60, and it is
thought that antibodies against these viral proteins can
bind to human HSP60 expressed on stressed endothe-
lial cells [143]. The proteins also share some homology
with nonstressed endothelial cell markers such as CD151,
CD49f, and connexin 45 (Cx45). It is believed that dur-
ing cytomegalovirus infection, antibodies generated against
these proteins can bind, by molecular mimicry, to the
surface markers on both nonstressed and already-stressed
endothelial cells causing apoptosis of endothelial cells, which
is considered to be one of the key early events in atheroscle-
rotic plaque formation. It has been also suggested that
endothelial cell stress induces HSP60 expression enhancing
the binding of circulating autoantibodies and amplifying
the endothelial cell damage [143]. Interesting results relat-
ing cytomegalovirus with atherosclerosis are derived from
studies investigating the expression of the viperin gene. The
human viperin gene has been suggested as a potential marker
for cytomegalovirus infection [144]. Viperin, which is highly
conserved among species, has a well-known antiviral eﬀect
and its use for the local treatment of cytomegalovirus has
been recently proposed. Viperin is expressed by endothelial
cells and SMCs in the vascular wall of disease vessels but
no expression has been detected in the normal arteries
[144].
Another pathogen associated with atherosclerosis is
enterovirus, especially the enterovirus group coxsackie B
virus [67]. High levels of enterovirus antibodies have been
detected in patients with myocardial infraction but it has not
yet been fully established whether the virus contributes to the
pathogenesis of the disease [67, 68, 145]. Other infectious
organisms that have been implicated in the pathogenesis of
atherosclerosis involve a member of the herpes virus family
that is known to induce atherosclerosis in chickens [146].
The virus alters cellular metabolism resulting in cholesterol
accumulation which is a common mechanism proposed for
all virally-induced atherosclerosis. There is also evidence that
the virus promotes smooth muscle cells (SMCs) proliferation
[147–150].
4. T-CELL ANTIGEN IMMUNE RESPONSES AND
ATHEROSCLEROTIC PLAQUE DEVELOPMENT
T lymphocytes are present in atherosclerotic plaques at
all stages of its development [15]. Most T cells within
atherosclerotic plaques are CD4+ and a small fraction of
the population consists of CD8+ T cells. CD4+ cells isolated
from human plaques have been found to express the αβ
T cell receptor (αβ TCR) [8, 151] that recognises antigens
presented in the context of HLA-DR in the surface of
APCs. The close proximity between T lymphocytes and
APCs within atherosclerotic plaques supports the view
that these lymphocytes are involved in antigen recognition
and antigen-specific proliferation in the shoulder regions
of atherosclerotic lesions [81]. They are attracted to the
tissues by chemokines and adhesion molecules expressed on
the surface of endothelial cells. Although the production
of IgM, also called natural auto-antibodies, seems to be
predominant in atherosclerosis, the presence in the serum
of IgG antibodies specific to oxLDL epitopes is indicative of
the involvement of CD4+ T cells in the process of aﬃnity
maturation and isotype class switching of B-cell clones
specific to atherogenic antigens [21].
The unbalance between pro- and anti-inflammatory
immune responses appears to be responsible for the develop-
ment of atherosclerosis. The activation of naı¨ve CD4+ T cells
generates one of the two major types of functionally diﬀerent
eﬀector T cells, the T-herper1 (Th1) or the Th2. The response
of the former cells is considered to be proinflammatory
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in the context of atherosclerosis and is characterised by
the secretion of IFN-γ, IL-12 and TNF-α which are all
involved in macrophage activation. IFN-γ also drives Th1
cell diﬀerentiation that can be inhibited by IL-10 [21]. Th2
response is considered to be anti-inflammatory due to the
secretion and action of IL-10 and other cytokines such as
IL-4, IL-5, and IL-13, all linked to B cell activation and
diﬀerentiation. Th2 diﬀerentiation is favoured by IL-4 and
it can be inhibited by IFN-γ. Th1 is the predominant T cell
subset found in atherosclerotic lesions [70, 152, 153].
The type of antibody produced, driven by Th1 or Th2
immune responses, also plays a key role in atherogenesis [21].
The synthesis of IgG1 antibodies indicates a predominant
Th2 response while IgG2a is indicative of Th1 responses [21].
The regulation of the balance between Th1 and Th2 immune
responses appears to be controlled by another T cell subset
referred to as regulatory T cells (Tregs) (reviewed in [154]).
It has been suggested that plaque size correlates with the
number of Th1 cells present within the lesions [155].
On the other hand, Th2 activation and proliferation
appears to be triggered by epitope-specific stimulation
[7, 156–160] or by the induction of natural antibodies
involved in the clearance of lipoprotein particles [95]. Auto-
antibodies against oxLDL have been found circulating in the
plasma. There is a correlation between the concentrations
of these antibodies in plasma and lesion size [161]. Recent
experimental evidence shows that pneumococcal vaccina-
tion using an animal model of atherosclerosis induces the
production of anti-oxLDL IgM antibodies, which inversely
correlates with the development of atherosclerotic plaques
[162]. It has been also proposed that IgM antibodies may
bind to oxLDL preventing its binding and degradation by
macrophages, or even prevent the uptake of apoptotic cells by
macrophages [163, 164]. However, the mechanisms involved
in the production of these antibodies or their precise role in
atherogenesis have not yet been addressed. Th2 responses are
also recognised in advanced stages of atherosclerosis, when
hypercholesterolemia is prominent and there seems to be a
shift of the immune response towards a Th2 type, indicating
that in late stages the immune system is trying to overcome
the pro-inflammatory damage [152].
Noticeably, the therapeutic correction of the balance
between these two types of responses has been pivotal for
the development of novel interventions, such as vaccines
against the development of the disease. Experiments carried
out using inbred stains of mice show that C57BL/6 mice are
more prone to develop Th1 responses and more atheroscle-
rosis than BALB/c mice which are prone to develop Th2
responses and consequently atheroresistant [165]. It has also
been noted that deletion of STAT6, a transcription factor
required for the activation of Th2 responses, prone these
mice to develop atherosclerosis [166]. Treatment of hyperc-
holesteremic mice with recombinant IFN-γ also accelerates
atherosclerotic plaque development [167], an eﬀect that is
reversed when mice receive the drug pentoxyfyllin, a potent
Th1 blocker [155].
Switching the immune response to a Th2 type can
be achieved by the expression of the anti-inflammatory
cytokine IL-10 which suppresses the eﬀect of proinflam-
matory cytokines such as IL-12 and IFN-γ [168, 169]. The
athero-protective eﬀect of IL-10 was noted even in mice fed
a high-fat diet. However, the treatment failed to influence
plasma cholesterol levels indicating that the IL-10 eﬀects
are due to modulation of the immune response involved in
intraplaque inflammation mechanisms [169]. Deficiency of
T-bet, a transcription factor required for Th1 diﬀerentiation,
in experimental animals significantly reduced atherosclerotic
lesions. This eﬀect was linked to a reduction in number
of proliferating smooth muscle cells in the intima layer
[170]. T-bet deficient mice have also shown a skewed
immune response towards the Th2-type when HSPs were
administered to these mice [170]. These findings suggest
that transcriptional regulation in T cell diﬀerentiation can
represent a good target to immunomodulate atherosclerosis.
Just recently the first report appeared on the possible role
of Th17 cells in cardiovascular disease [171]. Th17 cells are
characterised by IL-17 (or IL-17A), IL-17F, IL-6, TNF-α, and
IL-22 expressions. Their discovery has contributed to explain
crucial regulatory mechanisms which until now the classic
control by Th1 and Th2 or Treg cell-mediated mechanisms
could not explain. Th17 cells have been suggested to play
a key role in inflammation and autoimmunity. They have
also been involved in the pathogenesis of hypersensitivity
reactions. The study of their role in host defence mechanisms
has just recently started and promises to be another area
of high interest in cardiovascular biology research (see the
following articles for a comprehensive review of the recently
published literature on Th17 [172–177]). Cheng et al. have
suggested that Th17/Treg balance may play a key role in
controlling inflammation, plaque destabilization, and the
onset of acute coronary syndrome. They investigated this
hypothesis by assessing Th17/Treg functions through the
analysis of T cell frequencies, secretion of specific cytokines,
and production of key transcription factors in patients
with acute myocardial infarction, unstable angina and stable
angina. They found that Th17 cell numbers as well as its
cytokines (IL-17, IL-6, and IL-23) and transcription factor
(RORgammat) levels were significantly higher in patients
with acute coronary syndrome as compared to controls. The
study also showed a significant decrease in Treg number,
Treg-related cytokines (IL-10 and TGF-β1), and Foxp3 levels
in these patients as compared to stable angina and controls
suggesting a potential role for Th17/Treg imbalance in plaque
destabilization and the onset of ACS [171].
5. CONCLUSIONS
The multifactorial nature of atherosclerosis also applies to
the number and quality of antigens capable of inducing
proinflammatory/proatherogenic immune responses. The
evidence accumulated so far supports the view that oxLDL
is one of the most important atherogenic antigens, by virtue
of being the main trigger of monocytes/macrophage and
SMC infiltration, proliferation, and conversion in to foam
cells in the neointima layer. The key role of other self-
derived antigens such as HSPs and β2-GpI and the presence
of circulating antibodies against them, that in most cases
correlates with the clinical outcome, have been used to
Natalia Milioti et al. 9
justify the classification of atherosclerosis as an inflammatory
disease with an important autoimmune component. No less
important is the role of foreign antigens derived, among
others, from bacteria and viruses which might play a causal
and/or at least a bystander eﬀect contributing to the chronic
inflammatory process and its complications. Finally, the
role of T lymphocytes and the pro- and anti-inflammatory
balances controlled by their diﬀerent subsets has been shown
to be crucial in the development of the disease. These
responses are ultimately driven by the nature of the initial
stimuli (the antigen) and supported by a complex cascade
of events involving cytokines, components of the extra-
cellular matrix, and even gene expression regulators such
as transcription factors. Our current understanding of the
immunopathogenic mechanisms involved in atherosclerotic
plaque development has witnessed an enormous advance in
the last decade, and some of this knowledge constitutes the
foundation for the design of the next generation of drugs
to combat cardiovascular disease and reduce its devastating
consequences for the benefit of mankind.
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